Russian government sets out new restrictions for foreign drugmakers in state tenders

25 November 2016

The Russian government has designed new restrictions for the participation of foreign drugmakers in state tenders for the purchase of drugs for state needs, reports The Pharma Letter’s local correspondent.

According to the proposal of the Russian Ministry of Industry and Trade, an absolute advantage during state tenders for public procurement of drugs will be provided to those companies which use Russian-made substances/active ingredients in the production of drugs within Russia.

An official spokesman for Russian Health Minister Veronika Skvortsova said that, under the “Russian substance” rule, the legislation will mean those raw materials from which the molecule synthesis step has been carried out i Choosen Russia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK